Susama Verma1,2, Jungjae Lim3, Teaghen Buscemi-Kimmins4, Steven W Brose1,3. 1. Spinal Cord Injury Service, VAMC, Syracuse, New York, USA. 2. Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, USA. 3. Department of Physical Medicine & Rehabilitation, SUNY Upstate Medical University, Syracuse, New York, USA. 4. College of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
Abstract
CONTEXT: Amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases which cause progressive loss of upper and lower motor neurons at the spinal or bulbar level. ALS affects voluntary muscles of the body which control eating, talking, and moving. Individuals with ALS manifest difficulty breathing on their own due to weakness of the respiratory system. The average life expectancy of individuals with ALS is 2-5 years from the time of diagnosis, with death resulting from respiratory failure. There is no cure for ALS. At present, riluzole and edaravone are the only FDA-approved treatments that impact survival. Adverse reactions to edaravone include hypoxia and respiratory failure. To date, there are no published reports describing isolated dramatic respiratory improvement in ALS with continued global clinical worsening including limb and face function, particularly following edaravone use. FINDINGS: We present a case report of late stage bulbar ALS, in which a dramatic respiratory improvement is seen following edaravone use, and subsequent cessation. CONCLUSION/CLINICAL RELEVANCE: Isolated pulmonary decline and subsequent recovery following cessation of edaravone in the setting of continued systemic neurologic decline has not yet been described and may suggest potential for reversibility of edaravone-related pulmonary decline. Research is needed to evaluate this possibility further, and this case report may lead to further investigation to evaluate this possibility. Alternatively, although less likely, it is possible the observed that pulmonary improvement may either be beneficially attributed to edaravone, or unrelated to edaravone entirely - representing an undescribed phenomenon of isolated pulmonary decline and improvement in the setting of systemic continued ALS progression, possibly related to the bulbar subtype. Further investigation is warranted to evaluate both the role of edaravone in causing in a potentially reversible pulmonary decline upon cessation of the medication, and the possibility of other undefined variables including various subtypes of ALS contributing to this phenomenon.
CONTEXT: Amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases which cause progressive loss of upper and lower motor neurons at the spinal or bulbar level. ALS affects voluntary muscles of the body which control eating, talking, and moving. Individuals with ALS manifest difficulty breathing on their own due to weakness of the respiratory system. The average life expectancy of individuals with ALS is 2-5 years from the time of diagnosis, with death resulting from respiratory failure. There is no cure for ALS. At present, riluzole and edaravone are the only FDA-approved treatments that impact survival. Adverse reactions to edaravone include hypoxia and respiratory failure. To date, there are no published reports describing isolated dramatic respiratory improvement in ALS with continued global clinical worsening including limb and face function, particularly following edaravone use. FINDINGS: We present a case report of late stage bulbar ALS, in which a dramatic respiratory improvement is seen following edaravone use, and subsequent cessation. CONCLUSION/CLINICAL RELEVANCE: Isolated pulmonary decline and subsequent recovery following cessation of edaravone in the setting of continued systemic neurologic decline has not yet been described and may suggest potential for reversibility of edaravone-related pulmonary decline. Research is needed to evaluate this possibility further, and this case report may lead to further investigation to evaluate this possibility. Alternatively, although less likely, it is possible the observed that pulmonary improvement may either be beneficially attributed to edaravone, or unrelated to edaravone entirely - representing an undescribed phenomenon of isolated pulmonary decline and improvement in the setting of systemic continued ALS progression, possibly related to the bulbar subtype. Further investigation is warranted to evaluate both the role of edaravone in causing in a potentially reversible pulmonary decline upon cessation of the medication, and the possibility of other undefined variables including various subtypes of ALS contributing to this phenomenon.
Authors: Martin R Turner; Jakub Scaber; John A Goodfellow; Melanie E Lord; Rachael Marsden; Kevin Talbot Journal: J Neurol Sci Date: 2010-05-10 Impact factor: 3.181
Authors: Michael A van Es; Orla Hardiman; Adriano Chio; Ammar Al-Chalabi; R Jeroen Pasterkamp; Jan H Veldink; Leonard H van den Berg Journal: Lancet Date: 2017-05-25 Impact factor: 79.321
Authors: Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing Journal: Lancet Date: 2011-02-04 Impact factor: 79.321
Authors: Daniel Harrison; Paul Mehta; Michael A van Es; Elijah Stommel; Vivian E Drory; Beatrice Nefussy; Leonard H van den Berg; Jesse Crayle; Richard Bedlack Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2018-04-02 Impact factor: 4.092
Authors: Richard S Bedlack; Timothy Vaughan; Paul Wicks; Jamie Heywood; Ervin Sinani; Roger Selsov; Eric A Macklin; David Schoenfeld; Merit Cudkowicz; Alex Sherman Journal: Neurology Date: 2015-12-09 Impact factor: 9.910